Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Health Economic Publication Digest: Estimation of the maximum potential cost saving from reducing serious adverse events in hospitalized patients

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. 

In a recent publication, Larsen et al. explored potential healthcare savings in Denmark associated with the use of artificial intelligence-assisted vital signs monitoring systems. Based on the hypothesis, implementing these systems could potentially reduce the occurrence of serious adverse events in hospitalized patients. 

Utilizing Danish national registry data, the authors estimated economic benefits from the implementation of AI-assisted monitoring systems, highlighting significant potential savings from decreased length of hospital stay and fewer readmissions. However, the study highlighted the need for a more precise evaluation of the clinical effectiveness of AI-assisted technologies and detailed consideration of associated implementation costs.

Access the full-text article here.